E-mail: schrappe-ibfm@pediatrics.uni-kiel.de
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients
- Collaboration between Activating Mutations in JAK2 and Trisomy 21 in the Acute Lymphoblastic Leukemias of Down Syndrome (DS).
- Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study
- CONCURRENT DELETIONS OF IKZF1 AND PAX5, CDKN2A, CDKN2B OR PAR1 (IKZF1-PLUS) CONFER A VERY POOR PROGNOSIS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
- Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002
- Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study
- ERG DELETION EXERTS A CD2-DEPENDENT POSITIVE PROGNOSTIC IMPACT ON IKZF1-DELETED CHILDHOOD ALL
- GENOMIC AND DRUG RESPONSE PROFILING OF FATAL TCF3-HLF-POSITIVE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIES RECURRENT MUTATION PATTERNS AND NOVEL THERAPEUTIC OPTIONS
- IKZF1 DELETION STATUS DISCRIMINATES FOR OUTCOME IN IMATINIB-TREATED BCR-ABL1-POSITIVE CHILDHOOD ALL
- ILLEGITIMATE V(D)J - MEDIATED RECOMBINATION IS LINKED TO GENDER BIAS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
- Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?
- MINIMAL RESIDUAL DISEASE ANALYSIS IN NON-MRD BASED TREATMENT PROTOCOL FOR CHILDHOOD ALL: LOW RISK FEATURES TOGETHER WITH FAST MORPHOLOGICAL RESPONSE FAIL TO IDENTIFY SLOW-RESPONDERS WITHIN THE ALL IC-BFM 2002 STANDARD RISK GROUP
- Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT99 Study
- Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study
- Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia
- Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents
- Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study
- The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment
